-
11.发明授权公开(公告)号：US07972843B2
公开(公告)日：2011-07-05
申请号：US11980753
申请日：2007-10-31
申请人： Erich Hoffmann
发明人： Erich Hoffmann
CPC分类号： C07K14/005 , A61K2039/5252 , A61K2039/5254 , C12N7/00 , C12N2720/00063 , C12N2760/16122 , C12N2760/16151 , C12N2760/16163 , C12N2760/16222 , C12N2760/16263 , C12N2760/18663 , C12N2770/24263 , C12N2800/107 , C12N2800/40 , C12N2830/205 , C12N2830/34 , C12N2830/36 , C12N2830/85
摘要： The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus. Attenuated or inactivated RNA viruses produced by the present invention may be administered to a patient in need of vaccination by any of several routes including intranasally or intramuscularly.
摘要翻译： 本发明基于用于病毒RNA的有效细胞内合成的双重启动子系统（优选RNA pol I-pol II系统）的开发。 所得到的基于最小质粒的系统可用于合成任何RNA病毒，优选具有负单链RNA基因组的病毒。 当将系统的质粒引入合适的宿主细胞时，产生系统的病毒产物。 该系统的一个应用是生产用作疫苗抗原的减毒重配流感病毒。 通过共转染质粒产生的重配病毒可以包含编码来自目前感染群体的流感病毒的表面糖蛋白血凝素和神经氨酸酶的基因以及来自减毒流感病毒的内部基因。 本发明的优点是其多功能性; 该系统可以快速且容易地适应于合成任何RNA病毒的减毒版本。 通过本发明产生的减毒或灭活的RNA病毒可以通过包括鼻内或肌肉内的几种途径中的任何途径施用于需要接种疫苗的患者。
-
公开(公告)号：US20080311148A1
公开(公告)日：2008-12-18
申请号：US11980761
申请日：2007-10-31
申请人： Erich Hoffmann
发明人： Erich Hoffmann
CPC分类号： C07K14/005 , A61K2039/5252 , A61K2039/5254 , C12N7/00 , C12N2720/00063 , C12N2760/16122 , C12N2760/16151 , C12N2760/16163 , C12N2760/16222 , C12N2760/16263 , C12N2760/18663 , C12N2770/24263 , C12N2800/107 , C12N2800/40 , C12N2830/205 , C12N2830/34 , C12N2830/36 , C12N2830/85
摘要： The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus. Attenuated or inactivated RNA viruses produced by the present invention may be administered to a patient in need of vaccination by any of several routes including intranasally or intramuscularly.
-
公开(公告)号：US20080233560A1
公开(公告)日：2008-09-25
申请号：US11980753
申请日：2007-10-31
申请人： Erich Hoffmann
发明人： Erich Hoffmann
CPC分类号： C07K14/005 , A61K2039/5252 , A61K2039/5254 , C12N7/00 , C12N2720/00063 , C12N2760/16122 , C12N2760/16151 , C12N2760/16163 , C12N2760/16222 , C12N2760/16263 , C12N2760/18663 , C12N2770/24263 , C12N2800/107 , C12N2800/40 , C12N2830/205 , C12N2830/34 , C12N2830/36 , C12N2830/85
摘要： The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus. Attenuated or inactivated RNA viruses produced by the present invention may be administered to a patient in need of vaccination by any of several routes including intranasally or intramuscularly.
-
公开(公告)号：US20150283115A1
公开(公告)日：2015-10-08
申请号：US14621051
申请日：2015-02-12
IPC分类号： A61K31/4035
CPC分类号： A61K31/4035 , C12N7/00 , C12N15/11 , C12N2710/16663 , C12N2720/00063 , C12N2740/11063 , C12N2740/12063 , C12N2740/14063 , C12N2740/15063 , C12N2740/16063 , C12N2770/00063 , C12N2770/10063 , C12N2770/12063 , C12N2770/20063 , C12N2770/38063 , C12N2795/10263 , C12N2795/10363 , C12Q1/66 , C12Q1/6897
摘要： Described herein are methods for the identification or validation of compounds capable of causing ribosomal frameshifting and the use of said compounds to produce a stabilized SMNΔEx7 protein and treat Spinal Muscular Dystrophy.
摘要翻译： 本文描述了用于鉴定或验证能够引起核糖体移码的化合物的方法，以及使用所述化合物产生稳定的SMN＆Dgr; Ex7蛋白并治疗脊髓性肌营养不良症的方法。
-
公开(公告)号：US08986935B2
公开(公告)日：2015-03-24
申请号：US13058653
申请日：2009-08-13
IPC分类号： C12Q1/68 , G01N33/567 , C12Q1/02
CPC分类号： A61K31/4035 , C12N7/00 , C12N15/11 , C12N2710/16663 , C12N2720/00063 , C12N2740/11063 , C12N2740/12063 , C12N2740/14063 , C12N2740/15063 , C12N2740/16063 , C12N2770/00063 , C12N2770/10063 , C12N2770/12063 , C12N2770/20063 , C12N2770/38063 , C12N2795/10263 , C12N2795/10363 , C12Q1/66 , C12Q1/6897 , Y02A50/491
摘要： Described herein are methods for the identification or validation of compounds capable of causing ribosomal frameshifting and the use of the compounds identified by the methods described herein to produce a stabilized SMNΔEx7 protein and treat Spinal Muscular Atrophy.
摘要翻译： 本文描述了用于鉴定或验证能够引起核糖体移码的化合物的方法，以及通过本文所述的方法鉴定的化合物的用途，以产生稳定的SMN＆Dgr。Ex7蛋白并治疗脊髓性肌肉萎缩。
-
公开(公告)号：US20110213005A1
公开(公告)日：2011-09-01
申请号：US13058613
申请日：2009-08-13
CPC分类号： A61K31/4035 , C12N7/00 , C12N15/11 , C12N2710/16663 , C12N2720/00063 , C12N2740/11063 , C12N2740/12063 , C12N2740/14063 , C12N2740/15063 , C12N2740/16063 , C12N2770/00063 , C12N2770/10063 , C12N2770/12063 , C12N2770/20063 , C12N2770/38063 , C12N2795/10263 , C12N2795/10363 , C12Q1/66 , C12Q1/6897 , Y02A50/491
摘要： The present invention relates to compounds that modulate ribosomal frameshifting and nucleic acid constructs for use in methods for identifying or validation such compounds. In particular, the present invention relates to the use of nucleic acid constructs to identify or validate compounds capable of modulating the efficiency of programmed ribosomal frameshifting and the use of said compounds to inhibit the replication or infectivity of viruses that employ programmed ribosomal frameshifting.
摘要翻译： 本发明涉及调节核糖体移码和核酸构建体以用于鉴定或验证这些化合物的方法中的化合物。 特别地，本发明涉及核酸构建体用于鉴定或验证能够调节编程的核糖体移码效率的化合物的用途，以及使用所述化合物抑制采用程序化的核糖体移码的病毒的复制或感染性。
-
17.发明申请公开(公告)号：US20020164770A1
公开(公告)日：2002-11-07
申请号：US09844517
申请日：2001-04-27
发明人： Erich Hoffmann
IPC分类号： C12Q001/70 , C12N009/22 , C12N015/86 , C12N015/74 , C12N015/63 , C12N015/00 , C12N007/00
CPC分类号： C07K14/005 , A61K2039/5252 , A61K2039/5254 , C12N7/00 , C12N2720/00063 , C12N2760/16122 , C12N2760/16151 , C12N2760/16163 , C12N2760/16222 , C12N2760/16263 , C12N2760/18663 , C12N2770/24263 , C12N2800/107 , C12N2800/40 , C12N2830/205 , C12N2830/34 , C12N2830/36 , C12N2830/85
摘要： The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuraminidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus. Attenuated or inactivated RNA viruses produced by the present invention may be administered to a patient in need of vaccination by any of several routes including intranasally or intramuscularly.
摘要翻译： 本发明基于用于病毒RNA的有效细胞内合成的双重启动子系统（优选RNA pol I-pol II系统）的开发。 所得到的基于最小质粒的系统可用于合成任何RNA病毒，优选具有负单链RNA基因组的病毒。 当将系统的质粒引入合适的宿主细胞时，产生系统的病毒产物。 该系统的一个应用是生产用作疫苗抗原的减毒重配流感病毒。 通过共转染质粒产生的重配病毒可以包含编码来自目前感染群体的流感病毒的表面糖蛋白血凝素和神经氨酸酶的基因以及来自减毒流感病毒的内部基因。 本发明的优点是其多功能性; 该系统可以快速且容易地适应于合成任何RNA病毒的减毒版本。 通过本发明产生的减毒或灭活的RNA病毒可以通过包括鼻内或肌肉内的几种途径中的任何途径施用于需要接种疫苗的患者。
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.023 秒)
